Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Bruxelles  >  Ablynx    ABLX   BE0003877942

ABLYNX (ABLX)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
 News SummaryMost relevantAll newsSector newsTweets
Most relevant news about ABLYNX
01/22 Biotech M&A takes off as Sanofi and Celgene spend $20 billion
01/22 Sanofi digs deep to buy U.S. haemophilia group Bioverativ for $11.6 billion
01/22 New drugs recast $10 billion haemophilia market as Sanofi swoops in
01/22 ABLYNX : 22/01/2018 ablynx announces warrants exercise and conversion of bonds
01/22 ABLYNX : Announces warrants exercise and conversion of bonds
01/22 ABLYNX : Announces warrants exercise and conversion of bonds
01/18 European shares edge higher as cyclicals back in favour
01/18 ABLYNX : Largest Ablynx investor would consider improved Novo Nordisk bid
01/18 ABLYNX : 18/01/2018 publication in accordance with article 14 of the belgian law..
01/18 ABLYNX : Publication in accordance with article 14 of the belgian law of 2 may 2..
01/18 ABLYNX : Publication in accordance with article 14 of the belgian law of 2 may 2..
01/16 ABLYNX : 16/01/2018 publication in accordance with article 14 of the belgian law..
01/16 ABLYNX : Publication in accordance with article 14 of the belgian law of 2 may 2..
01/16 ABLYNX : Publication in accordance with article 14 of the belgian law of 2 may 2..
01/16 ABLYNX : Publication in accordance with article 14 of the belgian law of 2 may 2..
More most relevant news
All news about ABLYNX
01/22 Biotech M&A takes off as Sanofi and Celgene spend $20 billion
01/22 Sanofi digs deep to buy U.S. haemophilia group Bioverativ for $11.6 billion
01/22 New drugs recast $10 billion haemophilia market as Sanofi swoops in
01/22 ABLYNX : 22/01/2018 ablynx announces warrants exercise and conversion of bonds
01/22 ABLYNX : Announces warrants exercise and conversion of bonds
01/22 ABLYNX : Announces warrants exercise and conversion of bonds
01/18 European shares edge higher as cyclicals back in favour
01/18 ABLYNX : Largest Ablynx investor would consider improved Novo Nordisk bid
01/18 ABLYNX : 18/01/2018 publication in accordance with article 14 of the belgian law..
01/18 ABLYNX : Publication in accordance with article 14 of the belgian law of 2 may 2..
More news
Sector news : Biotechnology & Medical Research - NEC
08:48a Drug Firms Bet Billions on Biotech -- WSJ
01/22 Stocks hit record as senators reach deal to end shutdown
01/22 Big Drugmakers Pay Big Prices for Promising Biotechs
01/22 Dealmaking drives European stocks as equity melt-up continues
01/22 Biotech M&A takes off as Sanofi and Celgene spend $20 billion
01/22 CELGENE : to Buy Juno Therapeutics for $9 Billion -- 2nd Update
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
01/22 ABLYNX : Novo Offer Undervalues The Company
01/20 YOUR DAILY PHARMA SCOOP : Ablynx Takeover Battle, Acorda Takeover Speculation, O..
01/17 NOVO NORDISK : Don't Spoil The Ablynx Acquisition
01/09 YOUR DAILY PHARMA SCOOP : Ablynx Takeover Bid, Celgene Acquires Impact Biomedici..
01/08 Biotech Forum Daily Digest For Jan. 8th
01/08 Novo bids $3.1B for Ablynx
Latest Tweets
01/22ABLYNX ANNOUNCES WARRANTS EXERCISE AND CONVERSION OF BONDS -  
01/22ABLYNX ANNOUNCES WARRANTS EXERCISE AND CONVERSION OF BONDS  
01/22Ablynx : 22/01/2018 ABLYNX ANNOUNCES WARRANTS EXERCISE AND CONVERSION OF BOND.. 
01/22Ablynx : ANNOUNCES WARRANTS EXERCISE AND CONVERSION OF BONDS  
01/19Ablynx investor opens door to Novo deal at a higher price
1
More tweets
Qtime:49
Financials (€)
Sales 2017 66,6 M
EBIT 2017 -49,9 M
Net income 2017 -64,8 M
Finance 2017 157 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 37,7x
EV / Sales 2018 41,4x
Capitalization 2 665 M
Chart ABLYNX
Duration : Period :
Ablynx Technical Analysis Chart | ABLX | BE0003877942 | 4-Traders
Technical analysis trends ABLYNX
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Average target price 28,8 €
Spread / Average Target -19%
EPS Revisions
Managers
NameTitle
Edwin Moses Chief Executive Officer & Executive Director
Bo Jesper Hansen Chairman
Wim Ottevaere Chief Financial Officer
Antonin Rollet de Fougerolles Chief Scientific Officer
Robert K. Zeldin Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
ABLYNX65.83%3 265
CELLTRION, INC.--.--%33 774
IQVIA HOLDINGS INC5.21%21 423
LONZA GROUP2.62%20 876
INCYTE CORPORATION-1.64%19 660
ALNYLAM PHARMACEUTICALS, INC.-1.75%12 275